Covaxin gets WHO nod for emergency use listing

The WHO granted permission to Covaxin on Wednesday paving the way for many Non-Resident-Indians who are stuck in India after taking the vaccine and due to non-approval by the WHO, many countries were not allowing the Indians with Covaxin jab

PRAVASISAMWAD.COM

Finally, the Indian Covid-19 vaccine Covaxin has been included in emergency use listing by the World Health Organization.

The WHO granted permission to Covaxin on Wednesday paving the way for many Non-Resident-Indians who are stuck in India after taking the vaccine and due to non-approval by the WHO many countries were not allowing the Indians with Covaxin jab.

Recently the United States Centres for Disease Control and Prevention (CDC) gave clearance to Covaxin vaccinated individuals to travel to the US, with certain conditions.

Last week the Sultanate of Oman had also approved Covaxin for travel without quarantine. It allowed all passengers from India who received two doses of Covaxin at least 14 days before the estimated arrival date to travel to Oman without the requirement of quarantine.

“The Technical Advisory Group (an independent panel that provides the WHO with vaccine recommendations) has determined Covaxin meets standards for protection against COVID-19… the benefit of the vaccine far outweighs risks (and) the vaccine can be used.”

— WHO

Now the WHO cleared Covaxin for use in all age groups, above 18, over two doses.  “However, no recommendation has been made for use on children, and available data for use on pregnant women is insufficient to assess safety or efficacy,” WHO said.

“The Technical Advisory Group (an independent panel that provides the WHO with vaccine recommendations) has determined Covaxin meets standards for protection against COVID-19… the benefit of the vaccine far outweighs risks (and) the vaccine can be used,” the global health body said.

“Covaxin was also reviewed by WHO’s Strategic Advisory Group of Experts on Immunization (SAGE), and recommended use of this vaccine (is) in two doses, with an interval of four weeks, in all age groups 18+,” the WHO tweeted.

“Available data on vaccination of pregnant women with Covaxin are insufficient to assess vaccine safety or efficacy in pregnancy; studies in pregnant women are planned, including a pregnancy sub-study and a pregnancy registry,” it said.

************************************************************************

Readers

These are extraordinary times. All of us have to rely on high-impact, trustworthy journalism. And this is especially true of the Indian Diaspora. Members of the Indian community overseas cannot be fed with inaccurate news.

Pravasi Samwad is a venture that has no shareholders. It is the result of an impassioned initiative of a handful of Indian journalists spread around the world.  We have taken the small step forward with the pledge to provide news with accuracy, free from political and commercial influence. Our aim is to keep you, our readers, informed about developments at ‘home’ and across the world that affect you.

Please help us to keep our journalism independent and free.

In these difficult times, to run a news website requires finances. While every contribution, big or small, will makes a difference, we request our readers to put us in touch with advertisers worldwide. It will be a great help.

For more information: pravasisamwad00@gmail.com